Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

3(33%)

Results Posted

100%(2 trials)

Terminated

1(11%)

Phase Distribution

Ph phase_3

11%

Ph phase_1

11%

Ph phase_2

11%

Ph not_applicable

11%

Ph phase_4

56%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

1(11.1%)

Phase 2Efficacy & side effects

1(11.1%)

Phase 3Large-scale testing

1(11.1%)

Phase 4Post-market surveillance

5(55.6%)

N/ANon-phased studies

1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(2)

Terminated(1)

Other(2)

Detailed Status

unknown2

Recruiting2

Completed2

Active, not recruiting1

Not yet recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 11 (11.1%)

Phase 21 (11.1%)

Phase 31 (11.1%)

Phase 45 (55.6%)

N/A1 (11.1%)

Trials by Status

active_not_recruiting111%

unknown222%

recruiting222%

completed222%

not_yet_recruiting111%

terminated111%

Recent Activity

3 active trials

Showing 5 of 9

completedphase_4

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

NCT04370093

not_yet_recruitingphase_4

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

NCT06922656

active_not_recruitingphase_2

Clinical Trials (9)

Showing 9 of 9 trials

NCT04370093Phase 4

Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss

Completed

NCT06922656Phase 4

Can the Addition of Pioglitazone to SGLT2 Inhibitor in Type 1 Diabetic Patients Amplify the Decrease in HbA1c and Prevent the Increase in Plasma Ketone Concentration?

Not Yet Recruiting

NCT05919147Phase 2

The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia

Active Not Recruiting

NCT03878459Phase 4

Dapagliflozin Plus Pioglitazone in T1DM

Recruiting

NCT05501483Not Applicable

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

Recruiting

NCT05775380Phase 4

The Role of Pioglitazone in Vascular Transcriptional Remodeling

Unknown

NCT04123067Phase 1

Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke

Terminated

NCT04604223Phase 4

Effect of Pioglitazone on T2DM Patients With COVID-19

Unknown

NCT01183013Phase 3

30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9